Cargando…
Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Despite the clinical benefits of lowering levels of low-density lipoprotein cholesterol, many patients continue to experience cardiovascular events. This residual risk suggests that additional risk factors require aggressive modification to result in more effective prevention of cardiovascular disea...
Autores principales: | Scherer, Daniel J, Nicholls, Stephen J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378876/ https://www.ncbi.nlm.nih.gov/pubmed/25848301 http://dx.doi.org/10.2147/VHRM.S40134 |
Ejemplares similares
-
The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
por: Khan, Muhammad Shoaib, et al.
Publicado: (2021) -
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020) -
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Huston, Jessica, et al.
Publicado: (2023) -
Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014) -
Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review
por: Thakur, Mala, et al.
Publicado: (2020)